血小板活化在哮喘发病中的意义  

The role of platelet activation in the pathogenesis of asthma

作　　者：衡伟[1] 王光杰[1] 王兆钺[2] 马家用[1] 朱明清[3] 朱蓉梅[1] 

机构地区：[1]苏州医学院附属第一医院呼吸内科,215006 [2]苏州医学院附属第一医院,215006 [3]苏州医学院重点实验室

出　　处：《中华结核和呼吸杂志》2000年第6期343-346,共4页Chinese Journal of Tuberculosis and Respiratory Diseases

摘　　要：目的　探讨血小板活化在哮喘发病中的作用。方法　利用酶联免疫法及流式细胞仪分别测定 6 2例哮喘患者和 18名正常对照者血浆 11 去氢血栓烷B2 (11 DH TXB2 )、血栓烷 (TXB2 )浓度和血小板膜CD 6 2P的表达情况 ,并利用荧光酶联免疫法测定部分血清嗜酸细胞阳离子蛋白 (ECP)水平。结果　症状性哮喘组血浆 11 DH TXB2 浓度为 (33 2± 2 7)ng/L ,血小板CD 6 2P阳性百分比为 (2 3 8±3 0 ) % ,平均荧光强度为 2 75± 0 2 9;与健康对照组和缓解组比较差异有显著性 (P分别 <0 0 1、<0 0 5 )。缓解期哮喘与健康对照组比较仅血浆 11 DH TXB2 浓度差异有显著性 (P <0 0 5 )。哮喘发作时血小板活化水平与血清ECP及一秒钟用力呼气容积占预计值百分比 (FEV1占预计值百分比 )、最大呼气流量 (PEF)相关。结论　哮喘发作时存在血小板的异常活化 ,其活化程度与哮喘气道炎症及病情有一定相关性 。Objective To investigate whether platelets are activated during an asthmatic attack and to detect the correlation between platelet activation and severity of bronchial asthma Methods Plasma concentration of thromboxane B 2 (TXB 2) and 11 dehydro TXB 2 (11 DH TXB 2) and P selectin (CD 62P) on platelet surface were measured in 44 patients with asthma and in 18 normal individuals using ELISA and FCP The serum ECP level and pulmonary function were also analysed Results The plasma level of 11 DH TXB 2 and TXB 2 and the positive percentage of CD 62P on platelets were significantly increased in patients with acute asthma ( n =28) as compared with the control ( n =18, P <0 01) The plasma concentration of 11 DH TXB 2 and TXB 2 were decreased significanty after the control of asthma The level of platelet activation was correlated with ECP ( r =0 785, P <0 05),FEV 1%( r =-0 867, P <0 01 ) and PEF( r =-0 745, P <0 05) Conclusions These results suggest that there is an abnormal platelet activation in asthmatics, which can reflect the severity of bronchial asthma to a certain extent, although its exact,mechanism is unknown The platelets secret a wide range of biologically active substances capable of inducing or augmenting the airway inflammatory responses in asthma

关 键 词：哮喘 血小板活化 血栓烷B2 发病 

分 类 号：R562.25[医药卫生—呼吸系统]